GLP-1 Market
LLY $1208.74 ▲ +3.6% NVO $38.12 ▲ +0.2% PFE $29.21 ▲ +3.0% VKTX $25.47 ▼ -4.4% KLRA $10.74 ▼ -0.3% GPCR $21.88 ▼ -1.9% RHHBY $55.67 ▲ +3.5%
Market data delayed up to 20 min · Source: Twelve Data

Empowering you to have better conversations with your doctor.

Subscribe
About this data Sourced primarily from ClinicalTrials.gov — a listing isn't proof of safety or FDA approval.

Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.

Not yet reported

Virus-Specific Cytotoxic T Lymphocytes

Company
Children's Hospital of Philadelphia
Mechanism
Mechanism not yet reported
Route
Route not yet reported
Recruiting trials
10 recruiting

Efficacy results: Not yet reported

Find a Clinical Trial Near Me

10 recruiting studies currently listed on ClinicalTrials.gov.

Data source: ClinicalTrials.gov · trial data as of Oct 15, 2026

Find a Clinical Trial Near Me

See recruiting studies for Virus-Specific Cytotoxic T Lymphocytes and check eligibility with the study team.

Select conditions
Match
Treatment type

"Added to GLP-1" means the investigational treatment is being studied on top of an existing GLP-1-based therapy.

Your ZIP code is only used to calculate distance to trial sites — it isn't stored.

Trial details
  • Recruiting NCT NCT02007356

    A Study to Assess Safety and Feasibility of Direct Infusions of Donor-derived Virus-specific T-cells in Recipients of Hematopoietic Stem Cell Transplantation With Post-transplant Viral Infections Using the Cytokine Capture System®

    Not yet reported University Hospital, Basel, Switzerland 30 participants Est. completion 2026-12 1 site
    Other conditions: Adenovirus Infection, EBV, Cytomegalovirus Infections, Cytokine Capture System, Allogenic Disease
    View official trial listing →
  • Recruiting NCT NCT03266640

    Virus Specific Cytotoxic T-Lymphocytes (CTLs) for Refractory Cytomegalovirus (CMV)

    Not yet reported New York Medical College 20 participants Est. completion 2027-12-31 9 sites
    Other conditions: Cytomegalovirus Infections, Primary Immune Deficiency Disorder
    View official trial listing →
  • Recruiting NCT NCT03394365

    A Phase 3 Study of Tabelecleucel for Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure With Rituximab or Rituximab and Chemotherapy

    Not yet reported Pierre Fabre Medicament 115 participants Est. completion 2030-08 71 sites
    Other conditions: Epstein-Barr Virus+ Associated Post-transplant Lymphoproliferative Disease (EBV+ PTLD), Solid Organ Transplant Complications, Lymphoproliferative Disorders, Allogeneic Hematopoietic Cell Transplant, Stem Cell Transplant Complications
    View official trial listing →
  • Recruiting NCT NCT03665675

    Donor Virus-Specific CMV or AdV CTL to Treat CMV or AdV Reactivation or Disease After Solid Organ or HCT

    Not yet reported Sumithira Vasu 20 participants Est. completion 2027-06-20 2 sites
    Other conditions: Allogeneic Hematopoietic Stem Cell Transplantation Recipient, Cytomegalovirus, Donor, Solid Organ Transplantation Recipient, Adenovirus
    View official trial listing →
  • Recruiting NCT NCT04293042

    Treatment of BK Virus Infection With CTL Cells in Immunocompromised Transplant Patients

    Not yet reported Children's Hospital of Philadelphia 20 participants Est. completion 2029-01-30 1 site
    Other conditions: BK Polyomavirus
    View official trial listing →
  • Recruiting NCT NCT05183490

    R-MVST Cells for Treatment of Viral Infections

    Not yet reported Columbia University 36 participants Est. completion 2028-06 1 site
    Other conditions: Epstein-Barr Virus Infections, Cytomegalovirus Infections, Adenovirus, BK Virus Infection
    View official trial listing →
  • Recruiting NCT NCT07670468

    Evaluation of the Safety and Efficacy of LB-DTK-MV in Patients Diagnosed With Antiviral-Resistant CMV, BKV, or EBV Infection or Associated Diseases Following Anticancer Therapy or Allogeneic Hematopoietic Stem Cell Transplantation.

    Not yet reported, Not yet reported LucasBio 27 participants Est. completion 2027-06-04 1 site
    Other conditions: BKV Infection, EBV Infection, CMV Infection
    View official trial listing →
  • Recruiting NCT NCT07679412

    Evaluation of Safety and Efficacy of Autologous LB-DTK-CMV in Patients With Antiviral-Resistant and Refractory Cytomegalovirus Retinitis.

    Not yet reported LucasBio 5 participants Est. completion 2027-08-14 1 site
    Other conditions: CMV Retinitis
    View official trial listing →
  • Recruiting NCT NCT07685457

    Evaluation of Safety and Efficacy of Virus Specific T-Cell Administration in Pediatric Patients With Systemic Viral Infection Following Allogeneic Hematopoietic Stem Cell Transplantation.

    Not yet reported LucasBio 6 participants Est. completion 2027-05-20 1 site
    Other conditions: BKV Infection, CMV Infection, EBV Infection
    View official trial listing →
  • Recruiting NCT NCT07688759

    CMV-CMI in csCMVi After HSCT

    The First Affiliated Hospital of Soochow University 40 participants Est. completion 2028-08-31 1 site
    Other conditions: Cytomegalovirus Infections, Hematopoietic Stem Cell Transplantation (HSCT), Immune Reconstitution
    View official trial listing →
  • Completed NCT NCT00002663

    Biological Therapy in Treating Patients at High-Risk or With Lymphoma, Lymphoproliferative Disease, or Malignancies

    Not yet reported, Not yet reported Atara Biotherapeutics 58 participants Est. completion 2019-07 1 site Stand-alone
    Other conditions: EBV-induced Lymphomas, EBV-associated Malignancies, Transplant Patients With EBV Viremia at High Risk of Developing a Recurrent EBV Lymphoma
    View official trial listing →
  • Withdrawn NCT NCT00002956

    Immunotherapy for Lymphoproliferative Diseases Associated With Epstein-Barr Virus in Patients Who Have Undergone Organ Transplants

    Not yet reported University of Alabama at Birmingham Est. completion 2002-02 1 site Stand-alone
    Other conditions: Leukemia, Lymphoma
    View official trial listing →
  • Completed NCT NCT00005606

    Peripheral Blood Lymphocyte Therapy to Prevent Lymphoproliferative Disorders Caused by Epstein-Barr Virus in Patients Who Have Undergone Transplantation

    Not yet reported Northwestern University Est. completion 2003-09 1 site
    Other conditions: Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
    View official trial listing →
  • Status unknown NCT NCT00006100

    Allogeneic Epstein Barr Virus-Specific Cytotoxic T-Lymphocytes in Treating Patients With Progressive, Relapsed, or Refractory Hodgkin's Lymphoma

    Not yet reported Milton S. Hershey Medical Center 1 site
    Other conditions: Lymphoma
    View official trial listing →
  • Completed NCT NCT00063648

    Detection and Cytotoxic T Lymphocyte Therapy of Post-Transplant Lymphoproliferative Disorder After Liver Transplant

    Not yet reported National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) 50 participants Est. completion 2007-12 1 site
    Other conditions: Liver Disease, Lymphoproliferative Disorders
    View official trial listing →
  • Completed NCT NCT00078533

    Cytotoxic T-Lymphocytes for the Prophylaxis of Cytomegalovirus After Allogeneic Stem Cell Transplant

    Not yet reported Baylor College of Medicine 26 participants Est. completion 2011-06 2 sites
    Other conditions: Cytomegalovirus Infections
    View official trial listing →
  • Completed NCT NCT00590083

    Administration of Virus-Specific Cytotoxic T-Lymphocytes

    Not yet reported Baylor College of Medicine 14 participants Est. completion 2011-01 3 sites
    Other conditions: Adenovirus Infection
    View official trial listing →
  • Status unknown NCT NCT00690872

    Gemcitabine and Carboplatin Followed By Laboratory-Treated T Lymphocytes in Treating Patients With Metastatic or Locally Recurrent Epstein-Barr Virus-Positive Nasopharyngeal Cancer

    Not yet reported National Cancer Centre, Singapore 35 participants 1 site
    Other conditions: Head and Neck Cancer
    View official trial listing →
  • Completed NCT NCT00706316

    Administration of Epstein Barr Virus - Specific Cytotoxic T-Lymphocytes to Metastatic EBV-Positive Nasopharygneal Cancer

    Not yet reported University Health Network, Toronto 5 participants Est. completion 2012-11 1 site
    Other conditions: Nasopharyngeal Cancer
    View official trial listing →
  • Completed NCT NCT00711035

    Most Closely HLA Matched Allogeneic Virus Specific Cytotoxic T-Lymphocytes (CTL)

    Not yet reported, Not yet reported Baylor College of Medicine 50 participants Est. completion 2013-08 8 sites
    Other conditions: Adenovirus Infection, EBV Infection
    View official trial listing →
  • Active, not recruiting NCT NCT00840853

    Multi-virus CTLs Expressing CD19 Chimeric Receptors, CD19 Positive Malignancies Post SCT, MULTIPRAT

    Not yet reported Baylor College of Medicine 68 participants Est. completion 2031-04 2 sites
    Other conditions: Acute Lymphoblastic Leukemia (ALL), Chronic Lymphocytic Leukemia (CLL), Non Hodgkin's Lymphoma
    View official trial listing →
  • Completed NCT NCT01070797

    Administration of Rapidly Generated Multivirus-specific Cytotoxic T-Lymphocytes (VIRAGE)

    Not yet reported Baylor College of Medicine 10 participants Est. completion 2014-04 2 sites
    Other conditions: Adenovirus Infection, Epstein-Barr Virus Infections, Cytomegalovirus Infections, Stem Cell Transplant
    View official trial listing →
  • Active, not recruiting NCT NCT01430390

    In Vitro Expanded Allogeneic Epstein-Barr Virus Specific Cytotoxic T-Lymphocytes (EBV-CTLs) Genetically Targeted to the CD19 Antigen in B-cell Malignancies

    Not yet reported Memorial Sloan Kettering Cancer Center 19 participants Est. completion 2027-09 1 site
    Other conditions: Acute Lymphocytic Leukemia, Lymphoma
    View official trial listing →
  • Completed NCT NCT01460901

    Study of Donor Derived, Multi-virus-specific, Cytotoxic T-Lymphocytes for Relapsed/Refractory Neuroblastoma

    Not yet reported Children's Mercy Hospital Kansas City 5 participants Est. completion 2015-01 1 site
    Other conditions: Neuroblastoma
    View official trial listing →
  • Completed NCT NCT01475058

    CD19 CAR T Cells for B Cell Malignancies After Allogeneic Transplant

    Not yet reported, Not yet reported Fred Hutchinson Cancer Center 1 participants Est. completion 2014-07 1 site Stand-alone
    Other conditions: Philadelphia Chromosome Negative Adult Precursor Acute Lymphoblastic Leukemia, Philadelphia Chromosome Positive Adult Precursor Acute Lymphoblastic Leukemia, Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Immunoblastic Large Cell Lymphoma, Recurrent Mantle Cell Lymphoma, Refractory Chronic Lymphocytic Leukemia
    View official trial listing →
  • Status unknown NCT NCT01823718

    Cell Bank of Epstein Barr Virus Specific Cytotoxic T Lymphocytes

    Not yet reported Nantes University Hospital 18 participants Est. completion 2014-08 7 sites
    Other conditions: EBV Associated Lymphoma
    View official trial listing →
  • No Longer Available NCT NCT01945619

    Allogeneic Virus-Specific Cytotoxic T-Lymphocytes(CTL), Persistent/Recurrent Viral Infection Post-HSCT (EAP CHALLAH)

    Baylor College of Medicine 2 sites
    Other conditions: EBV Infection, CMV Infection, Adenoviral Infection
    View official trial listing →
  • Completed NCT NCT02108522

    Multivirus-specific T Cells for the Treatment of Virus Infections After Stem Cell Transplant

    Not yet reported AlloVir 82 participants Est. completion 2019-12 2 sites
    Other conditions: Infection
    View official trial listing →
  • Withdrawn NCT NCT02276820

    Most Closely Human Leukocyte Antigen (HLA)-Matched Adenovirus-specific T Lymphocytes (Viralym-A)

    Not yet reported AlloVir Est. completion 2019-12 2 sites
    Other conditions: Adenovirus Infection
    View official trial listing →
  • Withdrawn NCT NCT02313844

    Most Closely Human Leukocyte Antigen (HLA)-Matched BK Virus-specific T Lymphocytes (Viralym-B)

    Not yet reported AlloVir Est. completion 2019-12 2 sites
    Other conditions: BK Virus Infection
    View official trial listing →
  • Completed NCT NCT02313857

    Most Closely Human Leukocyte Antigen (HLA)-Matched CMV-specific T Lymphocytes (Viralym-C)

    Not yet reported AlloVir 10 participants Est. completion 2018-02 2 sites
    Other conditions: CMV Infections
    View official trial listing →
  • Completed NCT NCT02379520

    HPV-16/18 E6/E7-Specific T Lymphocytes, Relapsed HPV-Associated Cancers, HESTIA

    Not yet reported Baylor College of Medicine 35 participants Est. completion 2026-01 1 site
    Other conditions: Human Papillomavirus-Related Carcinoma, Human Papillomavirus Positive Oropharyngeal Carcinoma, Human Papillomavirus Positive Cervical Carcinoma, Human Papillomavirus Positive Anal Carcinoma, Human Papillomavirus Positive Vulvar Carcinoma, Human Papillomavirus Positive Penile Carcinoma
    View official trial listing →
  • Status unknown NCT NCT02456610

    Administration of Virus Specific CTLs for the Prophylaxis and Treatment of EBV/CMV Infections After HSCT in China

    Not yet reported Affiliated Hospital to Academy of Military Medical Sciences 30 participants Est. completion 2016-08 1 site
    Other conditions: Viral Infection
    View official trial listing →
  • Withdrawn NCT NCT02702427

    Virus-specific ImmunoTherapy Following Allogeneic Stem Cell Transplantation

    Not yet reported, Not yet reported St. Anna Kinderkrebsforschung Est. completion 2019-04-01 1 site
    Other conditions: Cytomegalovirus Infection, Adenovirus Infection
    View official trial listing →
  • Status unknown NCT NCT02779439

    Partially HLA-matched Third Party Antigen Specific T-cells for Infection Post-stem Cell or Solid Organ Transplantation

    Not yet reported University of Sydney 25 participants Est. completion 2018-03 1 site
    Other conditions: CMV Infection, EBV, Adenovirus
    View official trial listing →
  • Completed NCT NCT02973113

    Nivolumab With Epstein Barr Virus Specific T Cells (EBVSTS), Relapsed/Refractory EBV Positive Lymphoma (PREVALE)

    Not yet reported Baylor College of Medicine 8 participants Est. completion 2020-07-11 2 sites
    Other conditions: NonHodgkin Lymphoma, Lymphoproliferative Disorders, EBV Related Lymphoma, EBV-Related PTLD, Hodgkin Lymphoma, EBV Related Non-Hodgkin's Lymphoma, EBV Related Hodgkin's Lymphoma
    View official trial listing →
  • Active, not recruiting NCT NCT03180216

    T-Lymphocytes for Prevention or Treatment of Viral Infections Following Hematopoietic Stem Cell Transplantation

    Not yet reported Children's National Research Institute 32 participants Est. completion 2026-12 1 site
    Other conditions: Viral Infections, Bone Marrow Transplant Infection
    View official trial listing →
  • Terminated NCT NCT03769467

    Tabelecleucel in Combination With Pembrolizumab in Subjects With Epstein-Barr Virus-associated Nasopharyngeal Carcinoma (EBV+ NPC)

    Not yet reported, Not yet reported Atara Biotherapeutics 12 participants Est. completion 2021-08-19 7 sites
    Other conditions: Nasopharyngeal Carcinoma, Nasopharyngeal Neoplasms, Epstein-Barr Virus Infections, Epstein-Barr Viraemia, Epstein-Barr Virus-associated Nasopharyngeal Carcinoma (EBV+ NPC)
    View official trial listing →
  • Status unknown NCT NCT04389385

    COVID-19 Specific T Cell Derived Exosomes (CSTC-Exo)

    Not yet reported TC Erciyes University 60 participants Est. completion 2021-05-31 1 site
    Other conditions: Corona Virus Infection, Pneumonia
    View official trial listing →
  • Terminated NCT NCT04401410

    Anti-SARS Cov-2 T Cell Infusions for COVID 19

    Not yet reported Baylor College of Medicine 4 participants Est. completion 2021-10-12 1 site
    Other conditions: SARS-CoV 2, Viral Infection, COVID 19
    View official trial listing →
  • Terminated NCT NCT04933968

    Study of ALVR106 in Patients With Respiratory Viral Infections After Hematopoietic Cell and Solid Organ Transplant

    Not yet reported, Not yet reported AlloVir 17 participants Est. completion 2024-01-31 21 sites
    Other conditions: Respiratory Tract Viral Infections, Human Metapneumovirus (hMPV) Infection, Parainfluenza (PIV) Infection, Respiratory Syncytial Viral (RSV) Infection, Influenza Infection
    View official trial listing →
  • Status unknown NCT NCT05075837

    Adoptive T-cell Therapy for Resistant Viral Infections After Allogeneic HSCT

    Not yet reported Istituto Giannina Gaslini 10 participants Est. completion 2025-07-25 Stand-alone
    Other conditions: Viral Infection After HSCT
    View official trial listing →
  • Terminated NCT NCT05101213

    Study Assessing the Feasibility, Safety and Efficacy of Genetically Engineered Glucocorticoid Receptor Knock Out Virus Specific CTL Lines for Viral Infections in Immunosuppressed Cancer Patients

    Not yet reported M.D. Anderson Cancer Center 12 participants Est. completion 2026-08-03 1 site
    Other conditions: Adenovirus Infection, BK Virus Infection, Cytomegaloviral Infection, Hematopoietic and Lymphoid Cell Neoplasm, JC Virus Infection, Malignant Solid Neoplasm, Symptomatic COVID-19 Infection Laboratory-Confirmed
    View official trial listing →
  • Terminated NCT NCT05305040

    Study of Posoleucel (ALVR105,Viralym-M) for Multi-Virus Prevention in Patients Post-Allogeneic Hematopoietic Cell Transplant

    Not yet reported, Not yet reported AlloVir 451 participants Est. completion 2024-01-30 88 sites
    Other conditions: Adenovirus Infection, BK Virus Infection, Cytomegalovirus Infections, Epstein-Barr Virus Infections, Human Herpes Virus-6 Infection, JC Virus Infection
    View official trial listing →
  • Status unknown NCT NCT05447013

    Generation of SARS-CoV-2-specific T Lymphocytes From Recovered Donors and Administration to High-risk COVID-19 Patients

    Not yet reported, Not yet reported George Papanicolaou Hospital 182 participants Est. completion 2022-12-31 2 sites
    Other conditions: Severe COVID-19
    View official trial listing →
  • Completed NCT NCT05826496

    Exercise-induced Effects on Immune Parameters in Healthy Participants

    Not yet reported Per thor Straten 59 participants Est. completion 2025-02-10 1 site
    Other conditions: Healthy
    View official trial listing →
  • Status unknown NCT NCT06075927

    Multivirus-specific T Cells in the Treatment of Refractory CMV and/or EBV Infection After Allo-HSCT

    Not yet reported, Not yet reported Peking University People's Hospital 29 participants Est. completion 2025-10-30
    Other conditions: CMV Infection, EBV Infection, Stem Cell Transplant
    View official trial listing →
  • Completed NCT NCT06256341

    HHV-6-specific T-cell Reconstitution Among Children and Adolescents After Allogeneic Stem.

    Medical University of Graz 53 participants Est. completion 2023-11-01
    Other conditions: Allogeneic Stem Cell Transplantation
    View official trial listing →
  • Available NCT NCT07104591

    TETRAVI Expanded Access Program

    Baylor College of Medicine
    Other conditions: Epstein-Barr Virus Infection, Cytomegalovirus Infections, Adenovirus Infection, BK Virus Infection, JC Virus Infection, Viral Infections Post-Transplant, Post-Allogeneic Stem Cell Transplant Complications
    View official trial listing →
  • Not yet recruiting NCT NCT07638332

    Evaluation of the Safety and Efficacy of LB-DTK-BKV in Patients With BK Virus-Associated Hemorrhagic Cystitis Following Allogeneic Hematopoietic Stem Cell Transplantation

    Not yet reported, Not yet reported LucasBio 42 participants Est. completion 2028-03-01 9 sites
    Other conditions: Hemorrhagic Cystitis
    View official trial listing →
  • Not yet recruiting NCT NCT07873970

    25BT056: Basket Study of Viral Cytotoxic T Lymphocytes

    Not yet reported Children's Hospital of Philadelphia 35 participants Est. completion 2037-11 Stand-alone
    Other conditions: EBV Viremia, CMV Viremia, BK Viremia, Adenovirus, Post-transplant Lymphoproliferative Disorder, Viremia, Cytomegalovirus Enteritis, Adenovirus Infection, Epstein-Barr Virus Infection Reactivation, Epstein Barr Virus Infection, BK Virus Infection, Refractory Viral Infection, Opportunistic Viral Infection, Primary Immunodeficiency, Severe Combined Immunodeficiency (SCID), Inherited Immunodeficiency Diseases, Acquired Immunodeficiency, Stem Cell Transplant Complications, Solid Organ Transplant Complications
    View official trial listing →
Efficacy history

Not yet reported.

Safety

Not yet reported.

Sources

Also known as: Virus-Specific Cytotoxic T Lymphocytes, Virus-Specific Cytotoxic T Lymphocytes (vCTLs), vCTLs, Virus-specific T cells, Cytotoxic T lymphocyte therapy, Gamma-Capture Virus-Specific Cytotoxic T Lymphocytes, CliniMACS-Manufactured Virus-Specific Cytotoxic T Lymphocytes, Donor-Derived Virus-Specific Cytotoxic T Lymphocytes

Related On The Pen coverage

No related coverage yet.

This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.